Autres langues Eris Lifesciences Limited Bombay S.E.

Actions

ERIS

INE406M01024

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:49 23/04/2024			Varia. 5j.	Varia. 1 janv.
882 ^INR	-0,18 %		+3,24 %	-3,14 %

03/04	Eris Lifesciences achève l'acquisition des activités de formulation de Biocon Biologics en Inde	MT
15/03	Eris Lifesciences acquiert les activités de formulation de Biocon Biologics en Inde pour 12,42 milliards de roupies indiennes	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14/03
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16/02
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15/02
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13/02
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13/02
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08/02
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10/11
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09/11
Indian shares set to open higher tracking Asian peers	09/11
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08/11
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	08/11
Eris Lifesciences Limited Enters into Term Loan Agreement to Avail the Rupee Term Loan Facility from HDFC Bank Limited	29/09/23
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/08/23
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet	04/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eris Lifesciences Limited Bombay S.E.

Actions

ERIS

INE406M01024

Autres langues

Filtres